Compare AbCellera Biologics Inc (ABCL) vs Wells Fargo & Co (WFC) Price & Performance

AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.

The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.

Wells Fargo (WFC) trades at $87.21, up 1.99% on the day, with a bullish technical signal from moving averages and oscillators. The stock shows solid fundamentals with a P/E of 13.52, net income margin of 25.53%, and ROE of 12.7%. Recent earnings have been mixed, with a beat in Q3 2025 but misses in Q4 2025 and Q1 2026. The company announced a dividend of $0.45 payable in June 2026, and Q2 2026 earnings are expected on July 14, 2026, with an EPS estimate of 1.73.

The outlook for WFC is cautiously optimistic, supported by analyst consensus with a $98.25 price target and 45% buy ratings. Key opportunities include potential earnings growth and dividend increases post-Fed stress tests. Risks involve volatile cash flows, regulatory changes impacting debit card fees, and competitive pressures in the banking sector. The stock's valuation remains attractive, but investors should monitor upcoming earnings for confirmation of growth trends.